What is it about?
Increased circulating galactose-deficient IgA1 (Gd-IgA1) and subsequently complement activation both play important roles in the pathophysiology of IgA nephropathy (IgAN). However, their clinical utility, as biomarkers, was not systematically evaluated. This paper evaluated prognostic value of Gd-IgA1 and C3 as biomarkers in IgA nephropathy.
Featured Image
Why is it important?
Our findings show that galactose-deficient IgA1/C3 ratio was linearly associated with CKD progression events independently of clinical and biopsy characteristics.
Perspectives
I hope our findings make more researhers focus on Gd-IgA1/ C3 ratio and explore the clinical utility of Gd-IgA1/ C3 ratio.
Pei Chen
Peking University First Hospital
Read the Original
This page is a summary of: Plasma Galactose-Deficient IgA1 and C3 and CKD Progression in IgA Nephropathy, Clinical Journal of the American Society of Nephrology, September 2019, American Society of Nephrology,
DOI: 10.2215/cjn.13711118.
You can read the full text:
Contributors
The following have contributed to this page